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ABSTRACT
Chronic pain is a complex disorder with
multiple etiologies for which the pathologic
mechanisms are still largely unknown, making
effective treatment a difficult clinical task.
Achieving pain relief along with improved
function and quality of life is the primary goal
of pain clinicians; however, most patients and
healthcare professionals consider 30% pain
improvement to be clinically significant—a
success level that would be unacceptable in
other areas of medicine. Furthermore, patients
with chronic pain frequently have multiple
comorbidities, including depression and sleep
apnea, and most have seen several physicians
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prior to being seen by a pain specialist, have
more than three specific pain generators, and
are taking multiple medications. The addition
of further oral medications to control pain
increases the risk of drug–drug interactions
and side effects. However, topical analgesics
have the advantage of local application with
limited systemic levels of drug. Topical
therapies benefit from reduced side effects,
lower risk of drug–drug interactions, better
patient acceptability/compliance, and
improved tolerability. This two-part paper is a
review of topical analgesics and their potential
role in the treatment of chronic pain.
Keywords: Chronic pain; Neuropathic pain;
Rational topical polypharmacy; Skin
nociception; Topical analgesics
INTRODUCTION
Acute and chronic pain affects millions of
Americans. Each year, 25 million people will
experience an acute pain event (resolving in
\2 weeks), whereas 50 million live with chronic
pain [1]; furthermore, as the American
population ages, the incidence of chronic pain
is expected to only increase. For instance, up to
10% of all American adults report chronic pain;
however, this increases to 60% in those older
than 65 [2]. Missed work and increased
healthcare costs attributed to chronic pain
conditions have been estimated to exceed 100
billion dollars annually [3]. Chronic pain
manifests with both behavioral and physical
components, and it is known that genetics,
environment, and diet all impact the
generation of pain and analgesic
responsiveness. Most often, the clinical
presentation and treatment of chronic pain
patients is extremely complex, and simple
solutions or single modalilty therapy offer
limited benefit. Nevertheless, a general lack of
acceptance of this axiom may explain why
current chronic pain treatments are not more
efficacious. Clearly, there is a tremendous need
to better understand chronic pain mechanisms
and to create novel and effective multimodal
treatment options for clinicians and patients.
Topical analgesics (TAs) have been used for
centuries in the traditional medical approaches
of China and other countries. For example,
writings from before 600 BC on the treatment of
headache list a plethora of topical options,
including botanicals and animal-derived
products [4]. The first formal report of the
pain-reducing properties of topical capsaicin in
the West appeared in 1850 as a
recommendation to use an alcoholic hot
pepper extract for burning or itching
extremities [5]. Unfortunately, despite the long
history of TA use, their well-documented
benefits, and their current use in traditional
types of medicine, TAs are underutilized.
Neuropathic pain is a chronic condition of
the somatosensory nervous system that severely
impairs the health and quality of life of 5–10% of
humans, with a total United States economic
impact estimated at more than $600 billion
annually [6]. Neuropathic pain, by definition,
originates from neural pathology and
dysfunctions in the peripheral and/or central
nervous system (CNS) resulting in high levels of
cortical activity among regions known to
influence pain perception. Many types of
neuropathic pain originate within peripheral
tissues, such as skin, ostensibly driven by
hyperexcitability of primary afferents. As such,
topical approaches may be effective in
alleviating neuropathic pain at the source, and
this concept underlies most of the evidence for
the function of TAs. TAs can target regional pain
through affected skin, where they interfere with
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the peripheral nociceptive mechanisms directly,
by modulating the activity of small nerve fibers,
and/or indirectly, via non-neuron interactions
(e.g., skin resident cells, keratinocytes, and
monocyte-derived infiltrated immune cells). In
addition, TAs may reach deeper tissues and act
on underlying somatic peripheral nerves.
TAs can be delivered as liquids, ointments,
gels, powders, creams, semisolids, emulsions,
patches, foams, or aerosols. They are mixed with
adjuvants, which enhance viscosity and
permeation, and emollients and preservatives.
Effective TAs are water soluble and lipophilic,
with the delivery goals of reducing drug
concentration, increasing local tissue
absorption, and holding the drug at the
application site. Moreover, TAs avoid standard
issues that follow the oral ingestion of
medications, such as gastric ulceration, first-
pass hepatic metabolism, and problems
associated with variable serum concentrations.
However, there is distinct individual variation in
both skin physiology andmetabolism thatmight
affect the absorption and drug distribution of
TAs. Ultrasound, electricity, and lasers have all
been used to facilitate the permeability and
delivery of various topical preparations [7, 8].
This article will not discuss either these delivery
approaches or the use of TAs for venipuncture in
pediatrics. In this first part of this two-part article
on TAs, we discuss basic skin innervation and
immunocytochemical characteristics under
both normal and neuropathic conditions.
Insights into skin function and potential
therapies are derived from a discussion of
research models using topical capsaicin. We
also review other pharmacologic formulations
and delivery systems.
This review article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects




The skin is a protective barrier designed to
absorb daily physical abuse and environmental
extremes. Skin is also the largest sensory
organ, providing an essential interface
between an organism and external stimuli.
However, its exposed location and extreme
complexity predisposes the skin, and its
innervation, to hundreds of chronic
afflictions, many of which are associated
with chronic pain and lack effective, safe
therapeutic options, including postherpetic
neuralgia (PHN), diabetic peripheral
polyneuropathy (DPPN), and complex
regional pain syndrome (CRPS). In addition,
the skin and its innervation are especially
vulnerable to pharmacotoxic side effects. It is
a highly heterogenous organ that integrates
elements of integumentary, nervous, vascular,
immune, and endocrine functions as well as
self-renewing mechanisms. This complexity
provides a wide variety of important
functions including physical protection,
immunologic defense, extremely sensitive
multimodal stimulus detection,
thermoregulation, hormonal regulation,
pliability, and physical appeal. As such the
composition of the skin and the varieties of
innervation vary dependent upon different
functional demands needed over different
parts of the body surface.
A major challenge to the development of
more effective therapeutic strategies for
treating neuropathic pain originating from
the skin and its innervation is to identify the
nature of the underlying pathologies and how
they may differ across diseases and patients.
Multimolecular assessments of skin biopsies are
revealing previously unknown pathologies that
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provide valuable insight into the particular
symptoms of individual patients and the most
appropriate strategies for treatment. Analyses
of skin punch biopsies provide a method for
detecting potential pathologies that may
provide insight into chronic pain mechanisms
and potential therapeutic targets [9–15].
Immunocytochemical analyses of axons and
endings has become more selective and reliable
as well as increasingly viable for exploring
complex pain mechanisms and validating
human tissue targets [16–19]. Various
receptors are involved in cutaneous
nociception, a variety of which are listed in
Table 1.
The Paradoxical Loss of Epidermal
Endings
Until the late 1980s, it was widely believed that
the epidermis contained few sensory endings,
and that most of the small-caliber innervation
implicated in cutaneous sensations of pain (i.e.,
nociceptors) was located in the dermis.
However, the development of an antibody
against the enzyme ubiquitin C-terminal
hydrolase 1 (UCHL-1, also called protein gene
product 9.5 [PGP9.5]), which is enriched in
neuroendocrine cells, revealed extensive,
previously unknown innervation, with the
epidermis being a primary site of small-fiber
nociceptor endings (Fig. 1a, d) [17, 20–23].
Paradoxically, however, PGP9.5
immunolabeling of punch biopsies from
several types of intractable chronic pain
afflictions revealed a significant depletion of
this intraepidermal nociceptor innervation in
these neuropathic pain states (Fig. 1d) [9–15, 18,
19, 24]. Two hypotheses to explain this
apparent paradox are: (1) the deafferentation
hypothesis, which proposes that CNS neurons
may be sensitized by loss of input; and (2) the
irritable nociceptors hypothesis, which
proposes that the remaining innervation may
be hyperactive [25]. Several lines of evidence
have revealed that the remaining sensory
innervation is, indeed, hyperactive; however,
the source of the hyperactivity has yet to be
established [26–32]. One potential source may
be the selective loss of some innervation types
which normally have a regulatory impact,
whereas another source is likely to be that the
remaining innervation has increased branching
and changes in neurochemistry (Fig. 1d)—for
example, upregulation of the transient receptor
potential cation channel, subfamily V, member
1 (TRPV1) [17–19]. However, such changes have
yet to be systematically explored. Although the
density of epidermal innervation is generally
lower in painful skin, a substantial depletion of
innervation can also occur without pain
following a herpes zoster outbreak or due to
normal aging [33].











List is not exhaustive. Based on: Dubin AE, Patapoutian A.
Nociceptors: the sensors of the pain pathway. J Clin
Invest. 2010;120:3760–3772 and Gold MS, Gebhart GF.
Nociceptor sensitization in pain pathogenesis. Nat Med.
2010;16:1248–1257
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Pathologies of Epidermal Keratinocyte
Neural Chemistry
A contributing factor to the hyperactivity of
epidermal innervation may be pathologies
involving the signaling of epidermal
keratinocytes. Although keratinocytes are
typically regarded as nonexcitable cells, they
express numerous neurospecific signaling
molecules; however, the function of these
molecules is typically viewed in the context of
keratinocyte proliferation and differentiation.
Substantial recent evidence indicates that
keratinocytes have both algesic and analgesic
properties that are involved in sensory
transduction and the modulation of activity at
epidermal sensory endings. For example,
analgesic mechanisms involve the expression
of b-endorphin among the keratinocytes of the
upper stratum which can be released by
activation of the endothelin-1 receptor B (ETB)
and the cannabinoid 2 receptor (CB2), which
are coexpressed in the same keratinocytes of the
upper stratum (Fig. 1e). The release of
b-endorphin, in turn, may suppress the
activity of epidermal endings that express
l-opioid receptors, G-protein-activated inward-
rectifying potassium channels (GIRK), and the
proinflammatory neuropeptides calcitonin
gene-related peptide (CGRP) and substance P
(SP) [34, 35]. The algesic mechanisms involve
the keratinocyte production of ATP and the
b-isoform of CGRP, which may be released
through the activation of voltage-gated
sodium channels (NaV) expressed on the
keratinocytes (Fig. 1f) [36, 37]. The release of
ATP may activate purinergic receptors (e.g.,
P2X3), which are expressed primarily on
epidermal endings that lack CGRP and SP [38].
Recent evidence indicates that the
neurochemistry of keratinocytes obtained from
the painful skin of patients with PHN and CRPS
is skewed toward an over-representation of
algesic components (Fig. 1f) and an
underrepresentation of analgesic components.
Pathologies among Ab Fibers
The Ab cutaneous innervation is generally
regarded as mediating low-threshold
mechanoreceptive sensations, with
implications that it may play an inhibitory
role in pain modulation as hypothesized by the
gate theory. Currently, this innervation type
has received little attention in biopsy
assessments of skin associated with chronic
pain conditions, primarily due to the fact that
this innervation is concentrated in the glabrous
and hairy skin of the hands and feet, which are
rarely biopsied. However, multimolecular
labeling of glabrous and hairy skin, primarily
in rodents and monkeys and a few cases in
humans, have revealed that individual Meissner
corpuscles and piloneural complexes normally
have a complex highly ordered morphology
consisting of endings from multiple Ab fibers
with an intermingling of several types of
C-fibers (Fig. 1b, g) [22, 39–41]. Moreover,
both the Ab and C fiber endings normally
express immunochemically detected properties
typically associated with nociceptors. These
features indicate that the Meissner corpuscles
and the piloneural complexes are sites of
sensory integration that may have nociceptive
involvement. Another paradox of chronic pain
conditions is the common complaint that the
painful sites also manifest numbness, which has
been attributed to a likely loss of Ab fiber
innervation. However, assessments of
extensive skin samples of rhesus monkeys that
have naturally occurring type 2 diabetes and a
few humans with unmanageable CRPS that
required limb amputation revealed that
Meissner corpuscles and piloneural complexes
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were present, but were profoundly disorganized
(Fig. 1g, h) [17, 18]. These data suggest that the
numbness might be due to abnormal activity
from this innervation rather than a loss of
innervation, and aberrant piloneural complexes
observed in the patients with CRPS may
contribute to the profound mechanical
allodynia caused by slight movements of hairs.
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Pathologies among Vascular Innervation
Afferents containing CGRP/SP have been
implicated in an axon-reflex-mediated increase
in vascular dilation and permeability of
capillaries and precapillary arterioles in the
upper dermis as well as in pain sensation in
response to intense heat. However, relatively
little research has been directed toward the
extensive, dense, sensory innervation to the
arterioles and arteriole–venule shunts (AVS) in
the deeper dermis [16, 40, 41]. Nearly all of the
attention to the innervation of these deeper
vessels has been focused on the sympathetic
innervation, which is primarily noradrenergic,
with a recently identified cholinergic
contingent [16]. The sensory innervation of
deeper vessels consists of several types of C and
Ad fibers, most of which also express CGRP and
SP (Fig. 1c, i) [16, 40, 42–45]. This innervation is
presumably involved in monitoring vascular
dynamics and likely plays a vasodilatory
effector role to counter sympathetically
mediated vasoconstriction [44]. However,
recent evidence indicates that these arteriole
and AVS afferents may also contribute to
conscious tactile perceptions, including pain
[16]. The convergence of the sensory and
sympathetic innervation among cutaneous
vasculature may be a specific site of sudomotor
disorders and sympathetic involvement in
chronic pain conditions such as CRPS and
fibromyalgia, where profound pathologies of
this innervation have been observed in the skin
(Fig. 1i) [18, 46].
CLINICAL PHASE STUDIES
OF HUMAN EXPERIMENTAL PAIN
Capsaicin, 8-methyl-N-vanillyl-6-nonenamide,
is the active ingredient in chili peppers which
provokes a burning sensation by binding to a
heat-activated calcium channel, TRPV1. These
channels normally open between 37 and 45 C,
but, when bound, the threshold decreases to
less than 37 C or the physiologic body
temperature [47]. This stimulates the
exocytosis of SP, leading to mast cell
degranulation of histamine and serotonin
release from platelets. A flare and weal
response occurs rapidly while a poorly
localized, protracted dull pain lingers from
slow-conducting C nerve fibers. Mechanical
and heat hyperalgesia ensue as pain thresholds
decrease for central and peripheral nociceptors.
An area of mechanical allodynia and secondary
hyperalgesia occurs due to the activation of
adjacent dermatomes. When capsaicin is given
Fig. 1 Selected examples of chronic pain-related patholo-
gies detected by multimolecular immunoﬂuorescence
assessments of skin biopsies from humans and rhesus
monkeys. a–c Schematic illustration of all the types of
innervation in normal glabrous ﬁngertip based on a
compilation from several studies (from [41]). a C-ﬁber and
Ad-ﬁber innervation of the epidermis and arterioles.
b Ab-ﬁber innervation. c Vascular innervation. Broken-
line boxes indicate locations where immunolabelled images
are shown in corresponding d–i. d Changes in the
immunochemical characteristics in patients with postherp-
etic neuralgia (from [19]). e Expression of cannabinoid
receptor 2 and b-endorphin in normal epidermal kerati-
nocytes, which are part of an analgesic regulatory mech-
anism (from [34]). f Expression of NaV1.6 on epidermal
keratinocytes, which is increased in patients with CRPS
type 1 as part of an increased algesic mechanism (from
[36]). g Disarray of Ab-ﬁber lanceolate endings around
hair follicles of patients with CRPS type 1 (from [18]).
h Excess disorganized Ab-ﬁber Meissner corpuscles in the
dermal papillae of rhesus monkeys with type 2 diabetic
neuropathy (from [17]). i Excess innervation of arteriole
venule shunts of patients with ﬁbromyalgia (from [46]),
and loss of arteriole innervation coupled with hypertrophy
of the tunica media in patients with CRPS type 1 [5].
CGRP calcitonin gene-related peptide, CPRS chronic
regional pain syndrome, MBP maltose binding protein,
NPY neuropeptide Y, TH, tyrosine hydroxylase (positive
nerve terminals)
b
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intradermally, acute pain is elicited by the
activation of fast A fibers and as a direct effect
of capsaicin. Elements of chronic neuropathic
pain such as mechanothermal hyperalgesia and
allodynia are mediated through activation of C
fibers. These pain pathways are naturally
activated by tissue abrasions, burns, and
incisions. The chemical structure of capsaicin
is shown in Fig. 2.
There are two capsaicin research models—
the intradermal capsaicin and the heat/
capsaicin sensitization model. Both models
have been well validated as reliable means of
producing painful stimuli that include acute
sharp pain, burning sensation, mechanical and
heat hyperalgesia, and tactile allodynia.
Intradermal capsaicin-induced pain is dose
dependent, with a minimum dose requirement
of 10 lg to elicit a measurable response and
C100 lg for a robust reaction [48]. Both models
have been extensively studied with different
classes of pain medications that include opioids,
N-methyl-D-aspartic acid (NMDA) antagonists,
cannabinoids, sodium and/or calcium channel
antagonists, tricyclic antidepressants (TCAs),
and cyclooxygenase inhibitors. The
pharmacology of the two models appears to be
similar. Opioids, cannabinoids, and NMDA
antagonists significantly decrease pain and
allodynia in this human model. Other
nonopioid analgesics (intravenous lidocaine,
TCAs, and nonsteroidal anti-inflammatory
drugs [NSAIDs]) have minimal effect.
Gabapentin, a calcium channel modulator, has
shown equivocal results under this model, but
its analog, pregabalin, decreased capsaicin-
induced pain and hyperalgesia [49]. However,
if one looks closely at the studies, the
differences appear attributable to the different
drug doses and dose scheduling [50–52]. Table 2
shows properties of different classes of topical
drugs studied using capsaicin models.
A sodium channel antagonist (4030W92)
was shown to be ineffective in an intradermal
capsaicin model and had negative effect in a
multicenter trial on neuropathic pain with
mappable allodynia [53, 54]. Cannabis was
studied in this model, but the results showed
that a low dose was no different from placebo,
and a medium dose reduced, whereas a high
dose increased, pain [55].
The identification of the nature of the
underlying pathologies and how they may
differ from disease to disease and patient to
patient pose a major challenge to the
development of more effective strategies and
therapeutics for treating neuropathic pain
originating from the skin and its innervation.
Multimolecular assessments of skin biopsies are
just beginning to reveal previously unknown
pathologies that may provide valuable insight
into the particular symptoms of individual
patients and the most appropriate strategies
for their treatment. The density of epidermal
innervation has received major emphasis in
using skin biopsies as an analytical and
diagnostic tool for neuropathic pain. However,
these same skin biopsies also provide insight
into other potential contributors and
therapeutic targets for chronic pain such as
pathologies among neurochemical properties of
epidermal keratinocytes, perturbed Ab fiber
innervation, and aberrations among the
converging sensory and sympathetic
innervation on arterioles and AVS.
Fig. 2 Capsaicin
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FORMULATIONS
AND APPLICATIONS
When considering the use of a TA, the risk and
severity of adverse effects and drug–drug
interactions are less than for the same
analgesic administered systemically [56].
Obviously, this is clinically relevant when
managing a patient who has been prescribed
multiple concurrent systemic medications.
Recent guidelines regarding the
pharmacologic management of pain in older
adults emphasize this point [57]. Furthermore,
as TAs typically do not involve dose titration,
whereas many systemic agents do, this may
provide an additional benefit. Choosing which
TA to use depends upon the clinical setting in
which the medication is being used. For
example, application of the 5% lidocaine
patch, by protecting allodynic skin from
being stimulated, may reduce allodynia in
PHN [58].
Recently, three topical NSAIDs and the
capsaicin 8% patch (C8P) have been approved
by the Food and Drug Administration. Topical
preparations containing opioids, local
anesthetics (LAs), antidepressants, glutamate
receptor antagonists, a-adrenergic receptor
agonists, adenosine, cannabinoids, cholinergic
receptor agonists, gabapentinoids, prostanoids,
bradykinin, ATP, biogenic amines, and nerve
growth factor are each at various developmental
stages [59]. Considering using TAs that have
more than one mechanism of action might be
more efficacious than use of a single TA; for
example, the antinociceptive effects of topical
morphine may be enhanced by a topical
cannabinoid as suggested in a rat study [60].
This is intuitive for those who treat chronic pain
and could be considered ‘‘rational topical
polypharmacy’’.
CONCLUSION
TAs provide a therapeutic option with decreased
side effects and decreased drug–drug
interactions for patients with neuropathic and
other disabling chronic pain syndromes. The
range of potential targets that can be used as
TAs is expanding. The pharmaceutical industry
is taking interest in developing some of these
options into marketable products, all of which
should help patients with pain. In Part Two of
this article, we discuss specific drugs that can be
used as TAs as well as the potential to determine
through physical examination who would
benefit most from specific agents.
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